Vernalis plc (VER) Insider Carol Ferguson Buys 28,000 Shares
Vernalis plc (LON:VER) insider Carol Ferguson acquired 28,000 shares of the business’s stock in a transaction that occurred on Friday, September 30th. The shares were purchased at an average cost of GBX 41 ($0.54) per share, with a total value of £11,480 ($14,984.99).
Vernalis plc (LON:VER) opened at 41.3832 on Monday. Vernalis plc has a 1-year low of GBX 31.00 and a 1-year high of GBX 79.00. The firm’s market cap is GBX 184.21 million. The stock has a 50 day moving average price of GBX 43.63 and a 200 day moving average price of GBX 45.70.
Several research analysts have commented on VER shares. Stifel Nicolaus boosted their target price on Vernalis plc from GBX 94 ($1.23) to GBX 99 ($1.29) and gave the stock a “buy” rating in a research note on Tuesday, September 6th. Canaccord Genuity reissued a “buy” rating and set a GBX 84 ($1.10) target price on shares of Vernalis plc in a research note on Friday, July 8th. Panmure Gordon reissued a “buy” rating and set a GBX 76 ($0.99) target price on shares of Vernalis plc in a research note on Thursday, September 22nd. Shore Capital reissued a “house stock” rating on shares of Vernalis plc in a research note on Tuesday, July 19th. Finally, N+1 Singer reissued a “hold” rating and set a GBX 46 ($0.60) target price on shares of Vernalis plc in a research note on Thursday. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of GBX 73 ($0.95).
Vernalis plc Company Profile
Vernalis plc is a commercial-stage pharmaceutical holding company. The Company is engaged in the research, development and commercialization of pharmaceutical products for a range of medical disorders. The Company has two marketed products: Tuzistra XR in the United States prescription cough cold market, and frovatriptan, an acute treatment for migraine.
Receive News & Stock Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related stocks with our FREE daily email newsletter.